New Orleans, LA / Access Newswire / February 3, 2025

Kahn Swick & Foti, LLC (“KSF”) Remind Investors to File Lead Plaintiff Applications

Investors Alert: March 14, 2025 Deadline in Securities Class Action Lawsuit against Pacira BioSciences, Inc.

Kahn Swick & Foti, LLC, along with KSF partner and former Attorney General of Louisiana, Charles C. Foti, Jr., are reminding investors about the approaching deadline to file lead plaintiff applications in a securities class action lawsuit against Pacira BioSciences, Inc. (NasdaqGS: PCRX).

Investors who purchased the Company’s securities between August 2, 2023, and August 8, 2024, inclusive (the “Class Period”), have until March 14, 2025, to take action.

Pacira BioSciences, Inc. is a pharmaceutical company specializing in the development of non-opioid pain management therapies. The securities class action lawsuit alleges that the Company made false and misleading statements regarding the efficacy and safety of its flagship product, leading to financial losses for investors.

If you believe you have been affected by the alleged misconduct of Pacira BioSciences, Inc., and have suffered financial losses as a result of investing in the Company’s securities during the Class Period, it is crucial to act promptly and seek legal counsel to explore your options.

For more information on how to file a lead plaintiff application, visit the Kahn Swick & Foti, LLC website or contact their office directly.

Deadline: March 14, 2025

—

How Does This Affect Investors?

Investors who purchased Pacira BioSciences, Inc. securities between August 2, 2023, and August 8, 2024, should take immediate action by filing a lead plaintiff application in the ongoing securities class action lawsuit. By participating in the legal process, investors may seek to recover financial losses incurred as a result of alleged misconduct by the Company.

—

Global Impact

The securities class action lawsuit against Pacira BioSciences, Inc. highlights the importance of transparency and accountability in the pharmaceutical industry. As regulatory scrutiny increases and investors demand greater oversight, companies must uphold ethical standards to protect shareholder interests and maintain public trust.

—

Conclusion

As the deadline for filing lead plaintiff applications in the securities class action lawsuit against Pacira BioSciences, Inc. approaches, investors must take decisive action to protect their rights and seek potential recovery for financial losses. By staying informed and engaging in the legal process, investors can hold companies accountable for alleged misconduct and promote integrity in the financial markets.